Oncolytics Biotech Inc. (ONCY)
NASDAQ: ONCY · Real-Time Price · USD
1.190
-0.050 (-4.03%)
At close: Jul 23, 2025, 4:00 PM
1.160
-0.030 (-2.52%)
After-hours: Jul 23, 2025, 5:31 PM EDT

Company Description

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments.

The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer.

It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies.

Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.

Oncolytics Biotech Inc.
Oncolytics Biotech logo
CountryCanada
Founded1998
IPO DateNov 8, 1999
IndustryBiotechnology
SectorHealthcare
Employees28
CEOJared Kelly

Contact Details

Address:
322 11th Avenue SW, Suite 804
Calgary, AB T2R 0C5
Canada
Phone403-670-7377
Websiteoncolyticsbiotech.com

Stock Details

Ticker SymbolONCY
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyCAD
CIK Code0001129928
CUSIP Number682310875
ISIN NumberCA6823108759
SIC Code2834

Key Executives

NamePosition
Jared KellyChief Executive Officer and Director
Kirk J. Look C.A., CPAChief Financial Officer
Dr. Thomas C. Heineman M.D., Ph.D.Chief Medical Officer
Allison Hagerman P.Eng., P.M.P.Vice President of Product Development
Amy Goodowitz Levin B.S.N., R.N.Vice President of Clinical Operations
Jon PattonDirector of Investor Relations and Communication
Christophe DegoisVice President of Business Development
John Mark Lievonen B.B.A., CM, F.C.A., FCPA, LLD, M.B.A.Consultant

Latest SEC Filings

DateTypeTitle
Jul 23, 20256-KReport of foreign issuer
Jul 22, 20256-KReport of foreign issuer
Jul 16, 20256-KReport of foreign issuer
Jul 10, 20256-KReport of foreign issuer
Jul 8, 20256-KReport of foreign issuer
Jul 8, 20256-KReport of foreign issuer
Jun 30, 20256-KReport of foreign issuer
Jun 11, 20256-KReport of foreign issuer
May 23, 20256-KReport of foreign issuer
May 14, 20256-KReport of foreign issuer